Next-Generation Psychedelics Gain Attention in Biotech Industry

Next-generation psychedelics are gaining attention in the biotech industry as companies like Seaport Therapeutics and Gilgamesh Pharmaceuticals secure significant venture funding for their innovative approaches. These new psychedelic drugs aim to revolutionize mental health treatments, offering potential solutions beyond traditional psychedelics like psilocybin and LSD. Despite challenges in clinical use, the growing interest in psychedelic research highlights the industry’s shift towards innovative treatment approaches for mental health conditions.